secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001493152-23-038800
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus reports Phase 1 interim data for Decoy20: biomarker activation & transient AEs in first cohort
--------------------------------------------------------------------------------

- Interim data from first cohort (n=4) of Phase 1 INDP-D101 trial for Decoy20, dosed at 7x10^7 killed bacteria via 1-hour IV infusion.
- Treatment-related AEs included changes in hemodynamic parameters, transaminase elevations, lymphopenia; all resolved within 30 min to 3 days.
- Transient activation of innate and/or adaptive immune biomarkers observed in all patients as of Aug 31, 2023.
- Company to present full interim data at SITC 38th Annual Meeting on November 4, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223038800/0001493152-23-038800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223038800/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer